BioSpace News Archive

Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, will participate in the Bank of America Merrill Lynch Healthcare Conference at the Encore Hotel in Las Vegas, Nevada.

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement and/or leukotriene systems are implicated, today announced its financial results for the fourth quarter and full year ended December 31, 2018.

Safe Care Express staff are privileged to work with their patients and proud to offer some of the most technologically advanced treatment options in the state of Pennsylvania.

Marinomed Biotech AG, a globally active biopharmaceutical company with headquarters in Vienna, has announced the successful completion of the pivotal Phase III study for Budesolv.

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces positive initial Phase II clinical data from the first three of bullous pemphigoid (BP) patients in an ongoing clinical trial.

Twenty-seven mergers involving hospitals and health systems were announced in the first quarter of 2019, according to the latest analysis by Kaufman Hall, a leading provider of enterprise performance management software, and data and management consulting services, including a vibrant mergers and acquisitions practice

Healthy Directions LLC, and its parent company, Adaptive Health, LLC, have teamed up to add a clinically-studied pain relief cream to the bestselling Instaflex® line of nutritional supplements.

The University of Illinois at Chicago and Deerfield Management announced today the establishment of West Loop Innovations, LLC.

Discovery Behavioral Health, Inc. announced the appointment of Christian Losch as CEO at Pinelands Recovery Center of Medford, NJ.

As part of the U.S. Food and Drug Administration’s mission to protect the public health, outlined in our Medical Device Safety Action Plan, we are committed to continuing to strengthen and modernize how we take action to address device safety issues that emerge in the post-market in a more timely and effective way.